Search hospitals > Iowa > West Des Moines
Methodist West Hospital
Claim this profileWest Des Moines, Iowa 50266
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Lung Cancer
Conducts research for Recurrence
206 reported clinical trials
2 medical researchers
Summary
Methodist West Hospital is a medical facility located in West Des Moines, Iowa. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Lung Cancer, Recurrence and other specialties. Methodist West Hospital is involved with conducting 206 clinical trials across 393 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
HER2 positive
ER positive
Top PIs
Joshua LukenbillMedical Oncology and Hematology Associates-Des Moines4 years of reported clinical research
Expert in Cancer
Expert in Tumors
140 reported clinical trials
215 drugs studied
Robert J. BehrensIowa Methodist Medical Center4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
43 reported clinical trials
97 drugs studied
Clinical Trials running at Methodist West Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Squamous Cell Carcinoma
Prostate Cancer
Melanoma
Pancreatic Cancer
Bladder Cancer
Cutaneous Melanoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Methodist West Hospital?
Methodist West Hospital is a medical facility located in West Des Moines, Iowa. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Lung Cancer, Recurrence and other specialties. Methodist West Hospital is involved with conducting 206 clinical trials across 393 conditions. There are 2 research doctors associated with this hospital, such as Joshua Lukenbill and Robert J. Behrens.